Skip to main content

Web Exclusives

Meeting Highlights
ESMO Highlights
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
Read More
Meeting Highlights
ESMO Highlights, PARP Inhibitors
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Read More
Biosimilars
Best Practices for Integrating Biosimilars into Your Oncology Practice
Kashyap Patel, MD
Read More
Ovarian Cancer
New MIPS Rule Increases Performance Threshold for Positive Payment Adjustment
Read More
Ovarian Cancer
Combination Therapy May Improve Outcomes for Patients with Ovarian Cancer
Read More
Ovarian Cancer
State and Federal Legislation Addresses PBM Pricing Transparency
Read More
Ovarian Cancer, PARP Inhibitors
Proper Management of Toxicities Associated with PARP Inhibitors Is Essential for Optimizing Treatment Outcomes
Read More
Lung Cancer, Thyroid Cancer, FDA Updates
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Read More
Sarcoma, FDA Updates
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
Ovarian Cancer
PARP Inhibitor Use in Ovarian Cancer Expands Beyond Treatment for Recurrent Disease
Read More
Page 19 of 43
Results 181 - 190 of 428